Vor Biopharma Inc.
(VOR)
undefined
undefined%
At close: undefined
1.02
4.08%
After-hours Dec 13, 2024, 06:18 PM EST
Company Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients.
It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies.
The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers.
Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Vor Biopharma Inc.
| Country | United States |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 168 |
| CEO | Dr. Robert Ang M.B.A., M.D., MBBS |
Contact Details
Address: 100 Cambridgepark Drive Cambridge, Massachusetts United States | |
| Website | https://www.vorbio.com |
Stock Details
| Ticker Symbol | VOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001817229 |
| CUSIP Number | 929033108 |
| ISIN Number | US9290331084 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Ang M.B.A., M.D., MBBS | President, Chief Executive Officer & Director |
| Dr. Han Choi M.D. | Chief Financial Officer |
| Tania Philipp | Chief People Officer |
| Amy Quinlan | Interim Principal Accounting Officer |
| David Phillips M.B.A. | Senior Vice President & Head of Quality |
| Dr. Eyal C. Attar M.D. | Chief Medical Officer |
| Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. | Scientific Founder & Chairman of Scientific Advisory Board |
| Dr. Tirtha Chakraborty Ph.D. | Chief Scientific Officer |
| John C. King M.B.A. | Chief Commercial Officer & Head of Business Development |
| Samir Vattompadam M.S. | Senior Vice President of Portfolio Strategy & Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 09, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | 4 | Filing |
| Nov 08, 2024 | 4 | Filing |
| Nov 08, 2024 | 4 | Filing |
| Nov 08, 2024 | 4 | Filing |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 05, 2024 | 4 | Filing |
| Nov 05, 2024 | 4 | Filing |
| Nov 05, 2024 | 4 | Filing |